Sixteen drugmakers limiting discounts:
1. AbbVie
2. Amgen
3. AstraZeneca
4. Boehringer Ingelheim
5. Eli Lilly
6. Merck
7. Novartis
8. Novo Nordisk
9. Sanofi
10. UCB
11. United Therapeutics
12. Bristol Myers Squibb
13. Pfizer
14. GlaxoSmithKline
15. Gilead
16. Johnson & Johnson
“These limits reduce resources available to safety-net providers and increase the size of drug company profits. The biggest losers in this dispute are low-income and rural Americans who rely on the healthcare safety net for care when they are sick and preventive services to keep them healthy,” said Maureen Testoni, CEO and president of 340B Health.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.